Get started
Author

Alberto Arranz

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
2008 · Federico Pulido, José R Arribas, et al. · AIDS · 156
Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression: 48-Week Results of a Randomized, Controlled, Open-Label, Proof-of-Concept Pilot Clinical Trial (OK Study)
2005 · José R Arribas, Federico Pulido, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 151
Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis
2009 · Jose R Arribas, Rafael Delgado, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 109
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
2017 · Federico Pulido, Esteban Ribera, et al. · Clinical Infectious Diseases · 103
PDF
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
2020 · Sergio Serrano-Villar, Javier Martínez-Sanz, et al. · The Lancet HIV · 62
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
2009 · Federico Pulido, Ignacio Pérez-Valero, et al. · Antiviral Therapy · 61
PDF
Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
2023 · Javier Martínez-Sanz, Jorge Díaz-Álvarez, et al. · EBioMedicine · 58
PDF
Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics
2016 · Juan Berenguer, Antonio Rivero, et al. · Open Forum Infectious Diseases · 44
PDF
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression
2008 · F. Pulido, R. Delgado, et al. · Journal of Antimicrobial Chemotherapy · 42
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
2023 · Inés Suárez-García, Belén Alejos, et al. · Journal of Antimicrobial Chemotherapy · 34
PDF
Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients
2022 · Jorge Monserrat, Ana Gómez-Lahoz, et al. · International Journal of Molecular Sciences · 32
PDF
A Predictive Model and Risk Factors for Case Fatality of COVID-19
2021 · Melchor Álvarez-Mon, Miguel A. Ortega, et al. · Journal of Personalized Medicine · 28
PDF
Long‐Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV‐Infected Patients with Undetectable Virus Load
2004 · Paloma Gil, Miguel de Górgolas, et al. · Clinical Infectious Diseases · 28
Failure of Cetirizine to Prevent Nevirapine-Associated Rash: A Double-Blind Placebo-Controlled Trial for the GESIDA 26/01 Study
2004 · Hernando Knobel, José M Miró, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 18
Impact of the Innate Inflammatory Response on ICU Admission and Death in Hospitalized Patients with COVID-19
2021 · Jorge Monserrat, Angel Asunsolo, et al. · Biomedicines · 14
PDF
The changing pattern of tuberculosis and HIV co‐infection in immigrants and Spaniards in the last 20 years
2008 · M Velasco, V Castilla, et al. · HIV Medicine · 14
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
2021 · Óscar Brochado, Isidoro Martínez, et al. · Journal of Biomedical Science · 11
PDF
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients
2020 · Ana Carrero, Juan Berenguer, et al. · Clinical Infectious Diseases · 10
Discovering HIV related information by means of association rules and machine learning
2022 · Lourdes Araujo, Juan Martinez-Romo, et al. · Scientific Reports · 8
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial
2018 · Ignacio Pérez-Valero, Juan Pasquau, et al. · Journal of Antimicrobial Chemotherapy · 7
PDF
Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size
2025 · Erick De La Torre Tarazona, Elisa Moraga, et al. · Scientific Reports · 6
PDF
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks
2024 · Inés Suárez-García, Belén Alejos, et al. · Journal of Antimicrobial Chemotherapy · 6
PDF
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
2019 · Lorena Vigón, Sonia Vázquez-Morón, et al. · Scientific Reports · 6
[Reasons for antiretroviral treatment change in HIV+ patients in Spain in 2010-2011. SWITCH AUDIT Study].
2014 · Enric Pedrol, Pompeyo Viciana, et al. · PubMed · 6
Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT
2014 · Enric Pedrol, Pompeyo Viciana, et al. · Revista española de quimioterapia. Suplemento · 5
Works count: 30
Citation count: 1,022
H-index: 14
I10-index: 18
Year
Topic
Type